参考文献/References:
[1] Vergallo R,Crea F. Atherosclerotic plaque healing[J]. N Engl J Med,2020,383(9):846-857.
[2] Vergallo R,Porto I,D’Amario D, et al. Coronary atherosclerotic phenotype and plaque healing in patients with recurrent acute coronary syndromes compared with patients with long-term clinical stability: an in vivo optical coherence tomography study[J]. JAMA Cardiol,2019,4(4):321-329.
[3] Wang C,Hu S,Wu J, et al. Characteristics and significance of healed plaques in patients with acute coronary syndrome and stable angina: an in vivo OCT and IVUS study[J]. EuroIntervention,2019,15(9):e771-e778.
[4] Vergallo R,Crea F. Atherosclerotic plaque disruption and healing[J]. Eur Heart J,2020,41(42):4079-4080.
[5] Adriaenssens T,Allard-Ratick MP,Thondapu V, et al. Optical coherence tomography of coronary plaque progression and destabilization: JACC focus seminar part 3/3[J]. J Am Coll Cardiol,2021,78(12):1275-1287.
[6] Mann J,Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption[J]. Heart,1999,82(3):265-268.
[7] Virmani R,Kolodgie FD,Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions[J]. Arterioscler Thromb Vasc Biol,2000,20(5):1262-1275.
[8] Burke AP,Kolodgie FD,Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression[J]. Circulation,2001,103(7):934-940.
[9] Otsuka F,Joner M,Prati F, et al. Clinical classification of plaque morphology in coronary disease[J]. Nat Rev Cardiol,2014,11(7):379-389.
[10] Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The paul dudley white lecture 1995[J]. Circulation,1996,94(8):2013-2020.
[11] Shimokado A,Matsuo Y,Kubo T, et al. In vivo optical coherence tomography imaging and histopathology of healed coronary plaques[J]. Atherosclerosis,2018,275:35-42.
[12] Dai J,Fang C,Zhang S, et al. Frequency, predictors, distribution, and morphological characteristics of layered culprit and nonculprit plaques of patients with acute myocardial infarction[J]. Circulation: Cardiovascular Interventions,2020,13(10):e009125.
[13] Yin WJ,Jing J,Zhang YQ, et al. Association between non-culprit healed plaque and plaque progression in acute coronary syndrome patients: an optical coherence tomography study[J]. J Geriatr Cardiol,2021,18(8):631-644.
[14] Shrestha R,Shrestha A,Kan J, et al. A review in enormity of OCT and its enduring understanding of vulnerable plaque in coronary bifurcation lesion[J]. Int J Cardiovasc Imaging,2018,34(11):1679-1684.
[15] Feng X,Liu Y,Yang J, et al. Prevalence of Healed Plaque and Factors Influencing Its Characteristics Under Optical Coherence Tomography in patients with coronary artery disease: a systematic review, meta-analysis, and meta-regression[J]. Front Cardiovasc Med,2021,8:761208.
[16] Fracassi F,Crea F,Sugiyama T, et al. Healed culprit plaques in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2019,73(18):2253-2263.
[17] Li J,Sheng Z,Tan Y, et al. Association of plasma trimethylamine N-Oxide level with healed culprit plaques examined by optical coherence tomography in patients with ST-Segment elevation myocardial infarction[J]. Nutr Metab Cardiovasc Dis,2021,31(1):145-152.
[18] Nakajima A,Subban V,Russo M, et al. Coronary plaque and clinical characteristics of South Asian (Indian) patients with acute coronary syndromes: An optical coherence tomography study[J]. Int J Cardiol,2021,343:171-179.
[19] Russo M,Kim HO,Kurihara O, et al. Characteristics of non-culprit plaques in acute coronary syndrome patients with layered culprit plaque[J]. Eur Heart J Cardiovasc Imaging,2020,21(12):1421-1430.
[20] Nakajima A,Minami Y,Araki M, et al. Optical coherence tomography predictors for a favorable vascular response to statin therapy[J]. J Am Heart Assoc,2021,10(1):e018205.
[21] Kimura S,Cho S,Misu Y, et al. Optical coherence tomography and coronary angioscopy assessment of healed coronary plaque components[J]. Int J Cardiovasc Imaging,2021,37(10):2849-2859.
[22] Yin Y,Fang C,Jiang S, et al. In vivo evidence of atherosclerotic plaque erosion and healing in patients with acute coronary syndrome using serial optical coherence tomography imaging[J]. Am Heart J,2021,243:66-76.
[23] Nakajima A,Araki M,Kurihara O, et al. Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes[J]. J Thromb Thrombolysis,2022,53(2):241-248.
[24] Araki M,Yonetsu T,Russo M, et al. Predictors for layered coronary plaques: an optical coherence tomography study[J]. J Thromb Thrombolysis,2020,50(4):886-894.
[25] Araki M,Yonetsu T,Kurihara O, et al. Predictors of rapid plaque progression: an optical coherence tomography study[J]. JACC Cardiovasc Imaging,2021,14(8):1628-1638.
[26] Russo M,Fracassi F,Kurihara O, et al. Healed plaques in patients with stable angina pectoris[J]. Arterioscler Thromb Vasc Biol,2020,40(6):1587-1597.
[27] Okamoto H,Kume T,Yamada R, et al. Prevalence and clinical significance of layered plaque in patients with stable angina pectoris- evaluation with histopathology and optical coherence tomography[J]. Circ J,2019,83(12):2452-2459.
[28] Kramer MC,Rittersma SZ,de Winter RJ, et al. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death[J]. J Am Coll Cardiol,2010,55(2):122-132.
[29] Rittersma SZ,van der Wal AC,Koch KT, et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention[J]. Circulation,2005,111(9):1160-1165.
[30] Jia H,Dai J,Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study)[J]. Eur Heart J,2017,38(11):792-800.
[31] R?ber L,Koskinas KC,Yamaji K, et al. Changes in coronary plaque composition in patients with acute myocardial infarction treated with high-intensity statin therapy (IBIS-4): a serial optical coherence tomography study[J]. JACC Cardiovasc Imaging,2019,12(8 Pt 1):1518-1528.
[32] Kurihara O,Shinohara H,Kim HO, et al. Comparison of post-stent optical coherence tomography findings: Layered versus non-layered culprit lesions[J]. Catheter Cardiovasc Interv,2021,97(7):1320-1328.
[33] Kurihara O,Russo M,Kim HO, et al. Clinical significance of healed plaque detected by optical coherence tomography: a 2-year follow-up study[J]. J Thromb Thrombolysis,2020,50(4):895-902.
[34] Usui E,Mintz GS,Lee T, et al. Prognostic impact of healed coronary plaque in non-culprit lesions assessed by optical coherence tomography[J]. Atherosclerosis,2020,309:1-7.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(6):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[5]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[6]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[7]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[8]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[9]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[10]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]